Taimur Dad1, Hocine Tighiouart2, Alin Joseph1, Andrew Bostom3, Myra Carpenter4, Lawrence Hunsicker5, John W Kusek6, Marc Pfeffer7, Andrew S Levey1, Daniel E Weiner8. 1. Tufts Medical Center and Tufts University School of Medicine, Boston, MA. 2. Tufts Medical Center and Tufts University School of Medicine, Boston, MA; The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA; Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA. 3. Rhode Island Hospital, Providence, RI. 4. University of North Carolina, Chapel Hill, NC. 5. University of Iowa, Iowa City, IA. 6. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 7. Brigham and Women's Hospital, Boston, MA. 8. Tufts Medical Center and Tufts University School of Medicine, Boston, MA. Electronic address: dweiner@tuftsmedicalcenter.org.
Abstract
BACKGROUND: Cardiovascular disease (CVD) is the leading cause of death in kidney transplant recipients. Whether aspirin may reduce the risk for CVD, death, and kidney failure outcomes is uncertain. STUDY DESIGN: Post hoc cohort analysis of FAVORIT, a randomized trial examining the effect of homocysteine-lowering vitamins on CVD in kidney transplant recipients. SETTING & PARTICIPANTS: Prevalent adult kidney transplant recipients with hyperhomocysteinemia and stable kidney function from the United States, Canada, and Brazil participating in FAVORIT, with no known history of CVD. PREDICTOR: Aspirin use, with aspirin users matched to nonusers using a propensity score. OUTCOMES: Incident CVD events, kidney failure, all-cause mortality, a composite of CVD events or mortality, and a composite of kidney failure or mortality. Cox proportional hazards models with a robust variance to account for the correlation in outcomes within matched pairs were sequentially adjusted for demographic, clinical, and laboratory characteristics to assess the association between aspirin use and events. RESULTS:981 aspirin users were matched to 981 nonusers. During a 4-year mean follow up, there were 225 CVD events, 200 deaths, 126 kidney failure events, 301 composite kidney failure or mortality events, and 324 composite CVD or mortality events. Adjusted models showed no significant difference associated with aspirin use in risk for CVD events, all-cause mortality, kidney failure, composite of kidney failure or mortality, or composite of primary CVD events or mortality (HRs of 1.20 [95% CI, 0.92-1.58], 0.92 [95% CI, 0.69-1.23], 1.19 [95% CI, 0.81-1.74], 1.03 [0.82-1.31], and 1.11 [95% CI, 0.88-1.38], respectively). LIMITATIONS: We did not examine dose or continued use of aspirin after randomization. CVD history is dependent on participant report at baseline. Aspirin use was non-randomly assigned. CONCLUSIONS:Aspirin use is not associated with reduced risk for incident CVD, all-cause mortality, or kidney failure in stable kidney transplant recipients with no history of CVD.
RCT Entities:
BACKGROUND:Cardiovascular disease (CVD) is the leading cause of death in kidney transplant recipients. Whether aspirin may reduce the risk for CVD, death, and kidney failure outcomes is uncertain. STUDY DESIGN: Post hoc cohort analysis of FAVORIT, a randomized trial examining the effect of homocysteine-lowering vitamins on CVD in kidney transplant recipients. SETTING & PARTICIPANTS: Prevalent adult kidney transplant recipients with hyperhomocysteinemia and stable kidney function from the United States, Canada, and Brazil participating in FAVORIT, with no known history of CVD. PREDICTOR: Aspirin use, with aspirin users matched to nonusers using a propensity score. OUTCOMES: Incident CVD events, kidney failure, all-cause mortality, a composite of CVD events or mortality, and a composite of kidney failure or mortality. Cox proportional hazards models with a robust variance to account for the correlation in outcomes within matched pairs were sequentially adjusted for demographic, clinical, and laboratory characteristics to assess the association between aspirin use and events. RESULTS: 981 aspirin users were matched to 981 nonusers. During a 4-year mean follow up, there were 225 CVD events, 200 deaths, 126 kidney failure events, 301 composite kidney failure or mortality events, and 324 composite CVD or mortality events. Adjusted models showed no significant difference associated with aspirin use in risk for CVD events, all-cause mortality, kidney failure, composite of kidney failure or mortality, or composite of primary CVD events or mortality (HRs of 1.20 [95% CI, 0.92-1.58], 0.92 [95% CI, 0.69-1.23], 1.19 [95% CI, 0.81-1.74], 1.03 [0.82-1.31], and 1.11 [95% CI, 0.88-1.38], respectively). LIMITATIONS: We did not examine dose or continued use of aspirin after randomization. CVD history is dependent on participant report at baseline. Aspirin use was non-randomly assigned. CONCLUSIONS:Aspirin use is not associated with reduced risk for incident CVD, all-cause mortality, or kidney failure in stable kidney transplant recipients with no history of CVD.
Authors: Michael Pignone; Mark J Alberts; John A Colwell; Mary Cushman; Silvio E Inzucchi; Debabrata Mukherjee; Robert S Rosenson; Craig D Williams; Peter W Wilson; M Sue Kirkman Journal: Circulation Date: 2010-05-27 Impact factor: 29.690
Authors: Sidney C Smith; Jerilyn Allen; Steven N Blair; Robert O Bonow; Lawrence M Brass; Gregg C Fonarow; Scott M Grundy; Loren Hiratzka; Daniel Jones; Harlan M Krumholz; Lori Mosca; Thomas Pearson; Marc A Pfeffer; Kathryn A Taubert Journal: J Am Coll Cardiol Date: 2006-05-16 Impact factor: 24.094
Authors: Lori Mosca; Carole L Banka; Emelia J Benjamin; Kathy Berra; Cheryl Bushnell; Rowena J Dolor; Theodore G Ganiats; Antoinette S Gomes; Heather L Gornik; Clarissa Gracia; Martha Gulati; Constance K Haan; Debra R Judelson; Nora Keenan; Ellie Kelepouris; Erin D Michos; L Kristin Newby; Suzanne Oparil; Pamela Ouyang; Mehmet C Oz; Diana Petitti; Vivian W Pinn; Rita F Redberg; Rosalyn Scott; Katherine Sherif; Sidney C Smith; George Sopko; Robin H Steinhorn; Neil J Stone; Kathryn A Taubert; Barbara A Todd; Elaine Urbina; Nanette K Wenger Journal: J Am Coll Cardiol Date: 2007-03-20 Impact factor: 24.094
Authors: Andrew G Bostom; Myra A Carpenter; John W Kusek; Lawrence G Hunsicker; Marc A Pfeffer; Andrew S Levey; Paul F Jacques; Joyce McKenney Journal: Am Heart J Date: 2006-09 Impact factor: 4.749
Authors: A K Israni; J J Snyder; M A Skeans; Y Peng; J R Maclean; E D Weinhandl; B L Kasiske Journal: Am J Transplant Date: 2010-02 Impact factor: 8.086
Authors: Wolfgang Grotz; Sylvia Siebig; Manfred Olschewski; Christoph W Strey; Karlheinz Peter Journal: Transplantation Date: 2004-06-27 Impact factor: 4.939
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Andrew G Bostom; Myra A Carpenter; Lawrence Hunsicker; Paul F Jacques; John W Kusek; Andrew S Levey; Joyce L McKenney; Renee Y Mercier; Marc A Pfeffer; Jacob Selhub Journal: Am J Kidney Dis Date: 2008-11-20 Impact factor: 8.860
Authors: Shaifali Sandal; Sunjae Bae; Mara McAdams-DeMarco; Allan B Massie; Krista L Lentine; Marcelo Cantarovich; Dorry L Segev Journal: Am J Transplant Date: 2018-12-06 Impact factor: 8.086